Maze Therapeutics (MAZE) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Replimune Group (REPL) has outperformed Maze Therapeutics (MAZE) over the past year, gaining 183.9% versus a loss of 5.8%. Maze Therapeutics is the larger company by market cap ($1.46 billion vs $1.24 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAZE | REPL |
|---|---|---|
| Share price | $26.25 | $13.20 |
| Market cap | $1.46B | $1.24B |
| 1-day change | -0.68% | -0.38% |
| YTD return | -36.64% | +35.80% |
| 1-year return | -5.78% | +183.87% |
| 5-year return | — | -56.22% |
| EPS (TTM) | $-2.46 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $53.65 | $16.33 |
| 52-week low | $21.95 | $1.50 |
| Distance from 52-week high | -51.07% | -19.17% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +134.29% | +47.73% |
| Average volume | 556.08K | 4.20M |
| Shares outstanding | 55.55M | 94.22M |
| Employees | 141 | 465 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed MAZE by 189.6 percentage points over the past year.
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Healthcare · Biotechnology · 141 employees
About Replimune Group
REPL stock →Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Healthcare · Biotechnology · 465 employees
MAZE vs REPL FAQ
Which is bigger, Maze Therapeutics or Replimune Group?
Maze Therapeutics (MAZE) is larger, with a market capitalization of $1.46B compared with $1.24B for Replimune Group (REPL).
Which stock has performed better over the past year, MAZE or REPL?
REPL returned +183.87% over the past 12 months, compared with -5.78% for MAZE (price return, excluding dividends). Past performance does not predict future results.
Are Maze Therapeutics and Replimune Group in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.